Margaret A. Alexander - Sep 9, 2024 Form 3 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
President and COO
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
OVID
Transactions as of
Sep 9, 2024
Transactions value $
$0
Form type
3
Date filed
9/11/2024, 05:36 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OVID Common Stock 28.1K Sep 9, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 70K $3.73 Direct F2
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 2.02K $3.74 Direct F3
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 100K $2.72 Direct F4
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 10K $3.22 Direct F5
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 175K $2.50 Direct F6
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 169K $3.68 Direct F7
holding OVID Employee Stock Option (right to buy) Sep 9, 2024 Common Stock 315K $1.05 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on February 22, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date.
F2 25% of the shares subject to the Stock Option vested and became exercisable on August 2, 2022 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
F3 Fully vested and exercisable.
F4 25% of the shares subject to the Stock Option vested and became exercisable on February 3, 2023 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
F5 25% of the shares subject to the Stock Option vested and became exercisable on April 8, 2023 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
F6 25% of the shares subject to the Stock Option vested and became exercisable on February 23, 2024 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
F7 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
F8 50% of the shares subject to the Stock Option will vest and become exercisable on July 30, 2025 and the remaining shares will vest in 24 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.